After immigrating to the United State and becoming a U.S. citizen at the age of 18, Holocaust survivor Kurt Glover-Ettrich chose to give back to his new homeland by serving a 30-year career in the U.S. military. Today, as a Mayo Clinic volunteer, Kurt is giving back in new ways for the 22 years of regular care, treatment, and laboratory testing he’s received in response to the prostate cancer diagnosis that first brought him to Mayo Clinic.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS panels.
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Genitourinary Pathology.
Dr. Pandey is a nuclear radiology researcher working with a team to develop a new radioactive tracer to detect prostate cancer.
Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered.
This week’s Research Roundup highlights the development and validation of a prostate cancer genomic signature that predicts early androgen deprivation therapy (ADT) treatment response following radical prostatectomy.
This week’s Research Roundup highlights how the loss of FOXO1 cooperates with TMPRSS2-ERG overexpression to promote prostate tumorigenesis and cell invasion.
This week’s Research Roundup highlights individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease.
This week’s Research Roundup highlights how intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation.
In this month’s “Hot Topic,” Alicia Algeciras-Schimnich, Ph.D., will provide you with valuable information regarding the utility of the prostate specific antigen test, and how the calculation of a prostate health index, or phi, can help to stratify a patient’s risk for prostate cancer and reduce unnecessary biopsies.
The prostate health index or phi test reduces the need for prostate cancer biopsies by 30 percent.
This week’s Research Roundup highlights how the androgen receptor variant AR-V9 is co-expressed with AR-V7 in prostate cancer metastases and predicts abiraterone resistance.
Useful For Assessing the patient’s probability of having detectable prostate cancer when total prostate specific antigen (PSA) concentrations are between 4–10 ng/mL. Results from aRead more